The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.

"Evolution consists largely of molecular tinkering."-Following the famous concept of the molecular geneticist and medicine Nobel laureate François Jacob, in this review we describe the structural evolution of dopamine D3 receptor ligands from the natural agonist dopamine (DA) to highly potent and subtype selective new agents by bioisosteric tinkering with well-established and privileged or novel and fancy chemical functionalities and scaffolds. Some of the more than 200 ligands presented herein have already achieved therapeutic or scientific value up to now, some will most likely achieve it in the future. Hence, great importance is not only attached to the relationship between structure and activity of the ligands, but also to their utility as pharmacological tools in animal models or as therapeutics in patients with neurological diseases or other disorders.

[1]  C. Markham,et al.  Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry , 1986, Experimental Neurology.

[2]  P. Beardsley,et al.  Modulation of the discriminative stimulus effects of mu opioid agonists in rats: I. Effects of dopamine D2/3 antagonists , 2004, Behavioural pharmacology.

[3]  L. W. Cooke,et al.  Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. , 1995, The Journal of pharmacology and experimental therapeutics.

[4]  G. Skuza,et al.  Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. , 2003, Polish journal of pharmacology.

[5]  T. Heffner,et al.  4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. , 1990, Journal of medicinal chemistry.

[6]  V. Calabrese,et al.  N‐0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[7]  K. Chergui,et al.  Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.

[8]  R. Spealman,et al.  Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[9]  T. Heffner,et al.  Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. , 1990, Journal of Medicinal Chemistry.

[10]  H. Wikström,et al.  Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. , 1993, European journal of pharmacology.

[11]  J. Macher,et al.  Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. , 1996, American journal of medical genetics.

[12]  R. Mach,et al.  Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.

[13]  F. Boeckler,et al.  Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.

[14]  W. Im,et al.  Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.

[15]  P. Seeman,et al.  New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. , 2000, Brain research. Molecular brain research.

[16]  P. Jeffrey,et al.  Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  J. Witkin,et al.  Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907] , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  Jonathan A Javitch,et al.  Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.

[19]  A. Carlsson,et al.  (+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[20]  P. Beardsley,et al.  Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice , 2004, Pharmacology Biochemistry and Behavior.

[21]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[22]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[23]  S. Cooper,et al.  The effects of 7-OH-DPAT, quinpirole and raclopride on licking for sucrose solutions in the non-deprived rat , 2003, Behavioural Pharmacology.

[24]  Bryan L Roth,et al.  G-protein-coupled receptors at a glance , 2003, Journal of Cell Science.

[25]  H. Wikström,et al.  Structural analogues of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors. , 1999, Bioorganic & medicinal chemistry.

[26]  J. Schneider,et al.  Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism , 2001, Brain Research.

[27]  P. Gmeiner,et al.  Ex-chiral pool synthesis and receptor binding studies of 4-substituted prolinol derivatives , 2003 .

[28]  M. Scheideler,et al.  cis- and trans-2,3,3a,4,5,9b-Hexahydro-1H-benz[e]indoles: synthesis and evaluation of dopamine D2, and D3 receptor binding affinity , 1999 .

[29]  J. Palacios,et al.  High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.

[30]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[31]  M. Millan,et al.  Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells , 2004, Experimental Neurology.

[32]  Harald Hübner,et al.  Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists. , 2004, Bioorganic & medicinal chemistry.

[33]  P. Sokoloff,et al.  Disruption of nicotine conditioning by dopamine D3 receptor ligands , 2003, Molecular Psychiatry.

[34]  G. F. Koob,et al.  Pretreatment with the dopamine agonist 7‐OH‐DPAT shifts the cocaine self‐administration dose‐effect function to the left under different schedules in the rat , 1995, Behavioural pharmacology.

[35]  J. Ballesteros,et al.  Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.

[36]  P. Molinoff,et al.  Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  I. Tulloch Pharmacologic profile of ropinirole , 1997, Neurology.

[38]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[39]  M. Martres,et al.  The third dopamine receptor (D3) as a novel target for antipsychotics. , 1992, Biochemical pharmacology.

[40]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[41]  A. Zapata,et al.  D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens , 2002, Journal of neurochemistry.

[42]  H. Szechtman,et al.  Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder , 2002, Biological Psychiatry.

[43]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[44]  J. Kemp,et al.  Functional expression of human D3 dopamine receptors in differentiated neuroblastoma × glioma NG108–15 cells , 1994, British journal of pharmacology.

[45]  T. Heffner,et al.  Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists. , 2000, Journal of medicinal chemistry.

[46]  A. Carlsson,et al.  The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity , 2005, Journal of Neural Transmission / General Section JNT.

[47]  M. P. Turpin,et al.  A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor , 1995 .

[48]  P. Seeman,et al.  Multiple dopamine D4 receptor variants in the human population , 1992, Nature.

[49]  Y. Lecrubier,et al.  Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. , 1995, The American journal of psychiatry.

[50]  J. Javitch,et al.  Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.

[51]  J. Meador-Woodruff,et al.  Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.

[52]  C. Heidbreder,et al.  Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. , 2003, European journal of pharmacology.

[53]  H. Wikström,et al.  Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels , 1997, Brain Research.

[54]  S. Hjorth,et al.  Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. , 1981, Journal of Medicinal Chemistry.

[55]  M. Millan,et al.  The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. , 2000, European journal of pharmacology.

[56]  G. Schingnitz,et al.  Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. , 1992, European journal of pharmacology.

[57]  S. Konitsiotis,et al.  Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[58]  P. Goldman-Rakic,et al.  Localization of dopamine D4 receptors in GABAergic neurons of the primate brain , 1996, Nature.

[59]  J. Ginos,et al.  Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. , 1984, The Journal of pharmacology and experimental therapeutics.

[60]  J. Cannon Structure-activity relationships of dopamine agonists. , 1983, Annual review of pharmacology and toxicology.

[61]  A. Lieberman,et al.  Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study , 1997, Neurology.

[62]  J. Ballesteros,et al.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[63]  R. Mach,et al.  Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. , 2003, Current pharmaceutical design.

[64]  Susan R. George,et al.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.

[65]  M. Millan,et al.  [3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[66]  A Carlsson,et al.  A Paradigm Shift in Brain Research , 2001, Science.

[67]  SB-277011 GlaxoSmithKline. , 2001, Current opinion in investigational drugs.

[68]  M. Cador,et al.  Differential effects of dopaminergic agents on locomotor sensitisation and on the reinstatement of cocaine-seeking and food-seeking behaviour , 2003, Psychopharmacology.

[69]  M. Miller,et al.  Assessment of the discriminative stimulus effects of the D3 dopamine antagonist PNU-99194A in rats: comparison with psychomotor stimulants. , 1997, Behavioural pharmacology.

[70]  H. Wikström,et al.  Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism. , 2003, European journal of pharmacology.

[71]  T. Sotnikova,et al.  Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study). , 2001, Pharmacological research.

[72]  D. Grandy,et al.  Molecular diversity of the dopamine receptors. , 1993, Annual review of pharmacology and toxicology.

[73]  P. Gmeiner,et al.  Parallel synthesis and biological screening of dopamine receptor ligands taking advantage of a click chemistry based BAL linker. , 2005, Journal of combinatorial chemistry.

[74]  C. Schneider,et al.  Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. , 1987, Journal of medicinal chemistry.

[75]  M. Millan,et al.  Tetracyclic analogues of [+]-S 14297: Synthesis and determination of affinity and selectivity at cloned human dopamine D3 vs D2 receptors , 1997 .

[76]  R. Spealman Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.

[77]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[78]  M. Nader,et al.  Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. , 2005, Journal of medicinal chemistry.

[79]  Yoshinori Shichida,et al.  Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Newman,et al.  Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. , 2001, Journal of medicinal chemistry.

[81]  D. Evans,et al.  Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds. , 1992, Journal of medicinal chemistry.

[82]  R. Spealman,et al.  Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. , 2000, The Journal of pharmacology and experimental therapeutics.

[83]  H. Wikström,et al.  Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. , 1996, Journal of medicinal chemistry.

[84]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[85]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[86]  P. Gmeiner,et al.  Enantio- and diastereocontrolled dopamine D1, D2, D3 and D4 receptor binding of N-(3-pyrrolidinylmethyl)benzamides synthesized from aspartic acid. , 1999, Bioorganic & medicinal chemistry letters.

[87]  R. Todd,et al.  Characterization of the human dopamine D3 receptor expressed in transfected cell lines. , 1994, European journal of pharmacology.

[88]  M. Zarrindast,et al.  Morphine state-dependent learning: sensitization and interactions with dopamine receptors. , 2004, European journal of pharmacology.

[89]  N Rodenhuis,et al.  Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). , 2000, Journal of medicinal chemistry.

[90]  P. Sokoloff,et al.  Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1 Published on the World Wide Web on 24 November 1997. 1 , 1998, Brain Research Reviews.

[91]  C Dacquet,et al.  Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. , 1995, The Journal of pharmacology and experimental therapeutics.

[92]  M. Martres,et al.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.

[93]  D. Wong,et al.  Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline. , 1983, Journal of medicinal chemistry.

[94]  R. Vaccaro,et al.  Dissociation in the effects of the D2/D3 dopaminergic agonist quinpirole on drinking and on vasopressin levels in the rat , 2002, Neuroscience Letters.

[95]  Stephen J. Johnson,et al.  4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists , 1996 .

[96]  J. Maj,et al.  Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists. , 2001, Polish journal of pharmacology.

[97]  S. Hjorth,et al.  Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity. , 1982, Journal of medicinal chemistry.

[98]  H. Wikström,et al.  Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. , 1995, Life sciences.

[99]  P. Sokoloff,et al.  A functional test identifies dopamine agonists selective for D3 versus D2 receptors. , 1995, Neuroreport.

[100]  J. Hagan,et al.  The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. , 1998, Journal of medicinal chemistry.

[101]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[102]  G. Vauquelin,et al.  Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin , 1994, Brain Research.

[103]  C. Tamminga,et al.  D2-Family receptor distribution in human postmortem tissue: an autoradiographic study , 1995, Neuroreport.

[104]  I. Lucki,et al.  Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. , 2000, The Journal of pharmacology and experimental therapeutics.

[105]  P. Sokoloff,et al.  Identification of the dopamine autoreceptor in the guinea‐pig retina as D2 receptor using novel subtype‐selective antagonists , 2001, British journal of pharmacology.

[106]  W. Im,et al.  Agonist-induced [35S]GTPγS binding in the membranes of Spodoptera frugiperda insect cells expressing the human D3 dopamine receptor , 1997, Neuroscience Letters.

[107]  M. Millan,et al.  [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. , 1997, The Journal of pharmacology and experimental therapeutics.

[108]  M. Martres,et al.  [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome]. , 1990, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[109]  H. Sahraei,et al.  Involvement of dopamine D2 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat , 2002, Pharmacology Biochemistry and Behavior.

[110]  Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor. , 2001, Bioorganic & medicinal chemistry letters.

[111]  Torsten Kuwert,et al.  Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype. , 2004, Bioorganic & medicinal chemistry letters.

[112]  M. Hamon,et al.  Effects of a Dopamine D3 Receptor Ligand, BP 897, on Acquisition and Expression of Food-, Morphine-, and Cocaine-induced Conditioned Place Preference, and Food-seeking Behavior in Rats , 2003, Neuropsychopharmacology.

[113]  B. Ferger,et al.  The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study , 2000, Brain Research.

[114]  J. Schneider,et al.  Neuroprotective effects of pramipexole in young and aged MPTP-treated mice , 2001, Brain Research.

[115]  Robert H. Mach,et al.  Synthesis, in vitro dopamine D2 and D3 receptor binding and quantitative structure-activity studies on substituted 2,3-dimethoxy-N-(1- benzyl-4-piperidinyl)benzamides and related compounds , 1999 .

[116]  M. Papp,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[117]  M. Knowles,et al.  Expression and pharmacological characterization of the human D3 dopamine receptor. , 1994, The Journal of pharmacology and experimental therapeutics.

[118]  G. Phillips,et al.  Blockade of sensitisation-induced facilitation of appetitive conditioning by post-session intra-amygdala nafadotride , 2002, Behavioural Brain Research.

[119]  H. Wikström,et al.  Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT. , 1999, Bioorganic & medicinal chemistry.

[120]  Y. Lecrubier,et al.  Treatment of Negative Symptoms in Schizophrenia with Amisulpride , 1995, British Journal of Psychiatry.

[121]  G. Gessa,et al.  Apomorphine-induced penile erection and yawning: site of action in brain , 1987, Brain Research.

[122]  R. Depoortère,et al.  Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice , 1999, Neuropharmacology.

[123]  J. Hieble,et al.  4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist. , 1985, Journal of medicinal chemistry.

[124]  J. Welge,et al.  The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine , 2000, Brain Research.

[125]  H. Wikström,et al.  Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. , 2002, Journal of medicinal chemistry.

[126]  A. Horn,et al.  SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF THE HEXAHYDRO-4H-NAPHTH[1,2B][1,4]-OXAZINES - A NEW SERIES OF POTENT DOPAMINE RECEPTOR AGONISTS , 1985 .

[127]  Vincenzo Tortorella,et al.  Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. , 2002, Journal of medicinal chemistry.

[128]  D. Jackson,et al.  Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.

[129]  J. Schneider,et al.  Changes in striatal dopamine D2 receptors in relation to expression of and recovery from experimental parkinsonism , 2000, Brain Research.

[130]  G. Gonnet,et al.  Exhaustive matching of the entire protein sequence database. , 1992, Science.

[131]  Lei Shi,et al.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[132]  R. Depoortère,et al.  Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists , 1999, Neuropharmacology.

[133]  H. Shill,et al.  Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease , 2001, Clinical neuropharmacology.

[134]  B. Levant,et al.  The D3 dopamine receptor in cellular and organismal function , 1998, Psychopharmacology.

[135]  P. Gmeiner,et al.  Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: synthesis and dopamine receptor binding profiles. , 2000, Bioorganic & medicinal chemistry letters.

[136]  T. Uzbay,et al.  Bromocriptine and quinpirole, but not 7-OH-DPAT or SKF 38393, potentiate the inhibitory effect of L-NAME on ethanol-induced locomotor activity in mice , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[137]  P. Sokoloff,et al.  Two Intracellular Signaling Pathways for the Dopamine D3 Receptor: Opposite and Synergistic Interactions with Cyclic AMP , 1997, Journal of neurochemistry.

[138]  Thomas Boraud,et al.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.

[139]  J. Rubin,et al.  Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands , 1997 .

[140]  B. Sommer,et al.  The dopamine D2 receptor: two molecular forms generated by alternative splicing. , 1989, The EMBO journal.

[141]  R. Wise,et al.  Amphetamine-type reinforcement by dopaminergic agonists in the rat , 1978, Psychopharmacology.

[142]  P. J. Larsen,et al.  The preferential dopamine D3 receptor agonist cis-8-OH-PBZI induces limbic Fos expression in rat brain. , 1997, European journal of pharmacology.

[143]  P. Sokoloff,et al.  The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches , 1995, European Neuropsychopharmacology.

[144]  B. Levant The D3 dopamine receptor: neurobiology and potential clinical relevance. , 1997, Pharmacological reviews.

[145]  Rudie Kortekaas,et al.  In vivo Binding Behavior of Dopamine Receptor Agonist (+)−PD 128907 and Implications for the “Ceiling Effect” in Endogenous Competition Studies with [11C]Raclopride—a Positron Emission Tomography Study in Macaca mulatta , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[146]  A. Schapira,et al.  Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms , 2004, Journal of neurochemistry.

[147]  A. Cools,et al.  Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data , 1976, Psychopharmacologia.

[148]  J. Witkin,et al.  Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. , 1991, The Journal of pharmacology and experimental therapeutics.

[149]  Stanley J Watson,et al.  Dopamine Receptor mRNA Expression in Human Striatum and Neocortex , 1996, Neuropsychopharmacology.

[150]  J. Bockaert,et al.  Molecular tinkering of G protein‐coupled receptors: an evolutionary success , 1999, The EMBO journal.

[151]  R. Todd,et al.  Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. , 1994, The Journal of pharmacology and experimental therapeutics.

[152]  B. Everitt,et al.  Attenuation of Cue-Controlled Cocaine-Seeking by a Selective D3 Dopamine Receptor Antagonist SB-277011-A , 2003, Neuropsychopharmacology.

[153]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[154]  Zhen Yan,et al.  D3 Dopamine Autoreceptors Do Not Activate G-Protein-Gated Inwardly Rectifying Potassium Channel Currents in Substantia Nigra Dopamine Neurons , 2003, The Journal of Neuroscience.

[155]  K. Neve,et al.  Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. , 1997, Molecular pharmacology.

[156]  K. Svensson,et al.  PNU‐99194A: A Preferential Dopamine D3 Receptor Antagonist , 1998 .

[157]  A. Jaton,et al.  Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents. , 1986, Journal of medicinal chemistry.

[158]  K. Denicoff,et al.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study , 2004, Biological Psychiatry.

[159]  K. Cunningham,et al.  Dopamine D1 and D2 mediation of the discriminative stimulus properties ofd-amphetamine and cocaine , 2005, Psychopharmacology.

[160]  E. Domino,et al.  Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. , 1993, The Journal of pharmacology and experimental therapeutics.

[161]  M. Kleven,et al.  Dopamine D2 receptors play a role in the (-)-apomorphine-like discriminative stimulus effects of (+)-PD 128907. , 1997, European journal of pharmacology.

[162]  D. Sibley,et al.  [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. , 1995, European journal of pharmacology.

[163]  M. Millan,et al.  Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra , 2001, Brain Research.

[164]  C. Chidester,et al.  Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands. , 1993, Journal of medicinal chemistry.

[165]  K. Svensson,et al.  The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm , 1994, Pharmacology Biochemistry and Behavior.

[166]  M. Millan,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[167]  H. Kung,et al.  Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand. , 1993, Journal of medicinal chemistry.

[168]  R. North,et al.  D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. , 1996, Molecular pharmacology.

[169]  T. Petcher,et al.  Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine. , 1985, Journal of medicinal chemistry.

[170]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[171]  D. Hall,et al.  Pharmacological analysis of dopamine stimulation of [35S]‐GTPγS binding via human D2short and D2long dopamine receptors expressed in recombinant cells , 1996, British journal of pharmacology.

[172]  J. Joyce Multiple dopamine receptors and behavior , 1983, Neuroscience & Biobehavioral Reviews.

[173]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[174]  J. Welge,et al.  7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment , 2003, Neuropsychopharmacology.

[175]  Kevin J Black,et al.  A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[176]  P. Soubrié,et al.  Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking Behavior , 2004, Neuropsychopharmacology.

[177]  H. Kung,et al.  Synthesis of (.+-.)-2'-trans-7-hydroxy-2-[N-(3'-iodo-2'-propenyl)-N-n-propylamino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand , 1993 .

[178]  J. Schwartz,et al.  Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides. , 2005, Bioorganic & Medicinal Chemistry.

[179]  J. Joyce,et al.  Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja. , 1999, The Journal of pharmacology and experimental therapeutics.

[180]  F. Boeckler,et al.  Fancy bioisosteres: synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[181]  M. Millan,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[182]  P. Sokoloff,et al.  The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist. , 1995, European journal of pharmacology.

[183]  P. Strange,et al.  Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells. , 1999, Biochemical pharmacology.

[184]  P. Strange,et al.  Role of Conserved Serine Residues in the Interaction of Agonists with D3 Dopamine Receptors , 1999, Journal of neurochemistry.

[185]  M. Millan,et al.  A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. , 1998, The Journal of pharmacology and experimental therapeutics.

[186]  A. Carlsson,et al.  (S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: a new class of orally active 5-HT1A-receptor agonists. , 1993, Journal of medicinal chemistry.

[187]  M. Martres,et al.  Opposing Roles for Dopamine D2 and D3 Receptors on Neurotensin mRNA Expression in Nucleus Accumbens , 1994, The European journal of neuroscience.

[188]  P. Houck,et al.  Pramipexole in treatment-resistant depression: a 16-week naturalistic study. , 2002, Bipolar disorders.

[189]  I. Gyertyán,et al.  Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats , 2003, Brain Research Bulletin.

[190]  A. Newman,et al.  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[191]  P. Sokoloff,et al.  Development of Novel 1,2,3,4‐Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands , 2004, Chembiochem : a European journal of chemical biology.

[192]  T. Yanagihara,et al.  Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. , 1993, Biochemical and biophysical research communications.

[193]  K. Thewlis,et al.  Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor. , 1999, Bioorganic & medicinal chemistry letters.

[194]  P. Molinoff,et al.  Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle. , 1994, The Journal of pharmacology and experimental therapeutics.

[195]  P. Beardsley,et al.  The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice , 2003, Pharmacology Biochemistry and Behavior.

[196]  P. Mcgonigle,et al.  Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat , 1997, Neuroscience Letters.

[197]  J. Hagan,et al.  Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. , 2000, Journal of medicinal chemistry.

[198]  C. Tamminga,et al.  Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia , 1998, Journal of Neural Transmission.

[199]  S. Happe,et al.  Role of Dopamine Receptor Agonists in the Treatment of Restless Legs Syndrome , 2004, CNS Drugs.

[200]  L. Stein,et al.  The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats , 1992, Brain Research.

[201]  A. Carlsson,et al.  Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. , 2001, Journal of medicinal chemistry.

[202]  L. Coolen,et al.  Altered Behavioral Response to Dopamine D3 Receptor Agonists 7-OH-DPAT and PD 128907 Following Repetitive Amphetamine Administration , 2003, Neuropsychopharmacology.

[203]  C. Proud,et al.  Activation of Microtubule‐Associated Protein Kinase (Erk) and p70 S6 Kinase by D2 Dopamine Receptors , 1998, Journal of neurochemistry.

[204]  Harald Hübner,et al.  Practical ex-chiral-pool methodology for the synthesis of dopaminergic tetrahydroindoles , 2004 .

[205]  G. Mckenzie,et al.  Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene. , 1976, Journal of medicinal chemistry.

[206]  D. Evans,et al.  Dopamine D2 receptor binding properties of [3H]U-86170, a dopamine receptor agonist. , 1991, European journal of pharmacology.

[207]  S. Hjorth,et al.  Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists. , 1985, Journal of Medicinal Chemistry.

[208]  J. Clemens,et al.  Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists. , 1980, Journal of medicinal chemistry.

[209]  G. Riley,et al.  Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor : N-benzyl modifications , 1997 .

[210]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[211]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[212]  P. Sokoloff,et al.  D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties* , 2001, The Journal of Biological Chemistry.

[213]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[214]  D C Teller,et al.  Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). , 2001, Biochemistry.

[215]  G. Skuza,et al.  Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats. , 2004, Polish journal of pharmacology.

[216]  D. Evans,et al.  Pre- and postsynaptic dopaminergic activities of U-86170F , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[217]  J. Clemens,et al.  Degree of Selectivity of Pergolide as an Agonist at Presynaptic Versus Postsynaptic Dopamine Receptors: Implications for Prevention or Treatment of Tardive Dyskinesia , 1982, Journal of clinical psychopharmacology.

[218]  B. Ferger,et al.  Neurochemical findings in the MPTP model of Parkinson's disease , 2001, Journal of neural transmission.

[219]  B. Everitt,et al.  D3 receptor test in vitro predicts decreased cocaine self‐administration in rats , 1997, Neuroreport.

[220]  P. Gmeiner,et al.  Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. , 2000, Journal of medicinal chemistry.

[221]  P. Sokoloff,et al.  Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.

[222]  S. Senogles,et al.  D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway , 2004, Neuroscience Letters.

[223]  E. Novellino,et al.  Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. , 2003, Journal of medicinal chemistry.

[224]  J. van der Weide,et al.  Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation. , 1988, Journal of medicinal chemistry.

[225]  P. Strange,et al.  Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors , 1997, British journal of pharmacology.

[226]  G. Riley,et al.  Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor. , 1999, Bioorganic & medicinal chemistry letters.

[227]  P. Sokoloff,et al.  Selective Expression of Dopamine D3 Receptor mRNA in Proliferative Zones during Embryonic Development of the Rat Brain , 1997, The Journal of Neuroscience.

[228]  N. Robakis,et al.  Molecular cloning and characterization of the mouse dopamine D3 receptor gene: an additional intron and an mRNA variant. , 1995, DNA and cell biology.

[229]  A. Schapira Neuroprotection and dopamine agonists , 2002, Neurology.

[230]  G. Höfner,et al.  Synthesis, Pharmacological Investigation and Computational Studies on a Tricyclic Ergoline Analog with Selective Dopamine Autoreceptor Activity , 1995, Archiv der Pharmazie.

[231]  J. Hagan,et al.  Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. , 2000, The Journal of pharmacology and experimental therapeutics.

[232]  M. Martres,et al.  Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. , 1994, European journal of pharmacology.

[233]  P. Sokoloff,et al.  Role of dopamine D3 receptors in thermoregulation: a reappraisal , 2000, Neuroreport.

[234]  G. Koob,et al.  The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. , 1995, European journal of pharmacology.

[235]  J. Hagan,et al.  Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex , 2003, Neuropsychopharmacology.

[236]  Bernd Saletu,et al.  Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. , 1994 .

[237]  M. Millan,et al.  G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. , 1999, Molecular pharmacology.

[238]  M. Millan,et al.  Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. , 1999, Bioorganic & medicinal chemistry letters.

[239]  P. Gmeiner,et al.  Dopaminergic 7-aminotetrahydroindolizines: ex-chiral pool synthesis and preferential D3 receptor binding. , 2001, Bioorganic & medicinal chemistry letters.

[240]  P. Bonaventure,et al.  Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study , 1996, The Histochemical Journal.

[241]  J. Hubble,et al.  Pre‐clinical studies of pramipexole: clinical relevance , 2000, European journal of neurology.

[242]  Y. Wong,et al.  Gz signaling: emerging divergence from Gi signaling , 2001, Oncogene.

[243]  Sabine Borwege,et al.  Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor , 2004, BMC Biology.

[244]  Piercey Mf Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. , 1998 .

[245]  I. Gyertyán,et al.  Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011 , 2004, Behavioural pharmacology.

[246]  Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor. , 2000, Bioorganic & medicinal chemistry letters.

[247]  J. Hagan,et al.  Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking Behavior , 2003, Neuropsychopharmacology.

[248]  G. Riley,et al.  Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor , 1996 .

[249]  L. Bristow,et al.  Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors , 1998, Neuropharmacology.

[250]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[251]  P. Riederer,et al.  Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum , 2003, Journal of Neural Transmission.

[252]  P. Molinoff,et al.  Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors , 1995, Neuropsychopharmacology.

[253]  J. Yuan,et al.  NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.

[254]  G. N. Bancroft,et al.  Binding of [3H]PD 128907, a Putatively Selective Ligand for the D3 Dopamine Receptor, in Rat Brain: A Receptor Binding and Quantitative Autoradiographic Study , 1998, Neuropsychopharmacology.

[255]  J. Joyce Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. , 2001, Pharmacology & therapeutics.

[256]  G. Riley,et al.  Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. , 2000, European journal of pharmacology.

[257]  D. Kocjan On the interaction of the aromatic part of dopaminergic agonists with the receptor. , 1994, Journal of medicinal chemistry.

[258]  D. Wong,et al.  Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. , 1989, Journal of medicinal chemistry.

[259]  D. Grandy,et al.  Dopamine Receptor Gene Expression in the Human Medial Temporal Lobe , 1994, Neuropsychopharmacology.

[260]  J. Feldon,et al.  Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. , 2003, Biochemical pharmacology.

[261]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[262]  S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. , 1994, European journal of pharmacology.

[263]  J. Siuciak,et al.  The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors , 2004, Psychopharmacology.

[264]  K. Marder,et al.  A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. , 1992, Archives of neurology.

[265]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[266]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[267]  B Levant,et al.  Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. , 1995, European journal of pharmacology.

[268]  T. Hyde,et al.  Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[269]  B. Westerink,et al.  Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis. , 1991, European journal of pharmacology.

[270]  R. Mach,et al.  Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. , 2003, Bioorganic & medicinal chemistry.

[271]  M. Reith,et al.  A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors. , 2002, Bioorganic & medicinal chemistry letters.

[272]  K. Svensson,et al.  Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat , 2005, Journal of Neural Transmission / General Section JNT.

[273]  K. Svensson,et al.  Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology. , 1995, Journal of medicinal chemistry.

[274]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[275]  P. Sokoloff,et al.  BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization , 2001, Nature.

[276]  M. Piercey,et al.  Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. , 1996, European journal of pharmacology.

[277]  P. Sokoloff,et al.  Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice , 2004, Neuroreport.

[278]  S. Usuda,et al.  Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. , 1996, Journal of medicinal chemistry.

[279]  J. Clemens,et al.  Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. , 1979, Life sciences.

[280]  J. Kebabian,et al.  S-(+)-aporphines are not selective for human D3 dopamine receptors , 1994, Cellular and Molecular Neurobiology.

[281]  W. Oertel,et al.  A Non‐Ergot Dopamine Agonist, Pramipexole, in the Therapy of Advanced Parkinson's Disease: Improvement of Parkinsonian Symptoms and Treatment‐Associated Complications. A Review of Three Studies , 1997 .

[282]  J. Hagan,et al.  Dopamine D3 Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats , 2002, The Journal of Neuroscience.

[283]  G. Aston-Jones,et al.  Behavioural pharmacology: Breaking the chain of addiction , 1999, Nature.

[284]  Mark Froimowitz,et al.  Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists. , 1994, Journal of medicinal chemistry.

[285]  Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid. , 2003, Bioorganic & medicinal chemistry letters.

[286]  R. Beninger,et al.  A dopamine D3 receptor partial agonist blocks the expression of conditioned activity , 2002, Neuroreport.

[287]  P. Sokoloff,et al.  Role of the dopamine D3 receptor in reactivity to cocaine‐associated cues in mice , 2002, The European journal of neuroscience.

[288]  P. Sokoloff,et al.  N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands , 2003 .

[289]  M. Williams,et al.  A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists. , 1982, The Journal of pharmacology and experimental therapeutics.

[290]  Dopamine D3 Receptor Ligands with Antagonist Properties , 2002, Chembiochem : a European journal of chemical biology.

[291]  K. Thewlis,et al.  A novel series of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor , 1997 .

[292]  M. Caron,et al.  Recent advances in the molecular biology of dopamine receptors. , 1993, Annual review of neuroscience.

[293]  C. Humblet,et al.  G-Protein coupled receptors: models, mutagenesis, and drug design. , 1998, Journal of medicinal chemistry.

[294]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands , 2004 .

[295]  Robert H Mach,et al.  Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[296]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.

[297]  A. Zapata,et al.  Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses , 2001, Neuropharmacology.

[298]  P. Gmeiner,et al.  Enantiospecific synthesis and receptor binding of novel dopamine receptor ligands employing natural 4-hydroxyproline as a practical and flexible building block , 2003 .

[299]  J. Hagan,et al.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells , 1999, British journal of pharmacology.

[300]  P. Sokoloff,et al.  Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference , 2004, Psychopharmacology.

[301]  G. Riley,et al.  2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor , 1997 .

[302]  G. Gessa,et al.  (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. , 2001, European journal of pharmacology.

[303]  D. Sibley,et al.  Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase. , 1997, Biochemical and biophysical research communications.

[304]  M. Millan,et al.  Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. , 1994, European journal of pharmacology.

[305]  Lars Farde,et al.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 , 1996, Psychopharmacology.

[306]  C. Le Bihan,et al.  Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats , 2003, Psychopharmacology.

[307]  A. Argiolas,et al.  The neuropharmacology of yawning. , 1998, European journal of pharmacology.

[308]  Effects of ropinirole on motor behavior in MPTP-treated common marmosets , 2000, Pharmacology Biochemistry and Behavior.

[309]  Z. Vogel,et al.  Adenylyl Cyclase Interaction with the D2 Dopamine Receptor Family; Differential Coupling to Gi, Gz, and Gs , 1999, Cellular and Molecular Neurobiology.

[310]  I. Laszlovszky,et al.  Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats , 2005, Psychopharmacology.

[311]  A. Markham,et al.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.

[312]  M. Reith,et al.  Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. , 2004, Bioorganic & medicinal chemistry.

[313]  D. Helmeste,et al.  Dopamine D4 receptors. , 2000, Japanese journal of pharmacology.

[314]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[315]  P. Novak,et al.  Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson’s disease , 2001, Expert review of neurotherapeutics.

[316]  J. Hagan,et al.  Anxiolytic profile of ropinirole in the rat, mouse and common marmoset , 2000, Psychopharmacology.

[317]  M. Millan,et al.  Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors , 2000, Neuropharmacology.

[318]  H. Wikström,et al.  Thiophene analogs of naphthoxazines and 2-aminotetralins: bioisosteres with improved relative oral bioavailability, as compared to 5-OH-DPAT. , 2000, European journal of pharmacology.

[319]  S. Hjorth,et al.  N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity. , 1979, Journal of medicinal chemistry.

[320]  L. Snyder,et al.  Alternative transcripts of the rat and human dopamine D3 receptor. , 1991, Biochemical and biophysical research communications.

[321]  M. Millan,et al.  Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate , 2004, Experimental Neurology.

[322]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[323]  A. Carlsson,et al.  Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. , 1994, Journal of medicinal chemistry.

[324]  R. Mach,et al.  Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D(2) and D(3) receptors. , 2001, Bioorganic & medicinal chemistry.

[325]  H. Wikström,et al.  2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents. , 1998, Bioorganic & medicinal chemistry.

[326]  K. Wicke,et al.  The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. , 2001, European journal of pharmacology.

[327]  D. Sibley,et al.  Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. , 1995, European journal of pharmacology.

[328]  D. Middlemiss,et al.  Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells , 1999, British journal of pharmacology.

[329]  J. Legeai,et al.  Synthèse de dérivés aminés du tétrahydro-4,5,6,7 benzothiazole. I: Amines et N-méthylamines en positions 4, 5, 6 et 7 à activité dopaminergique centrale , 1984 .

[330]  M. P. Turpin,et al.  Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor , 1996 .

[331]  H. Kung,et al.  [125I](S)-trans-7-OH-PIPAT: a potential spect imaging agent for sigma binding sites. , 1994, Life sciences.

[332]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[333]  J. Hagan,et al.  Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats , 2003, Synapse.

[334]  M. E. Lajiness,et al.  Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. , 1994, Molecular pharmacology.

[335]  Angelo Bifone,et al.  Selective dopamine D3 receptor antagonist SB‐277011‐A potentiates phMRI response to acute amphetamine challenge in the rat brain , 2004, Synapse.

[336]  M. Nader,et al.  The effects of benzamide analogues on cocaine self-administration in rhesus monkeys , 1999, Psychopharmacology.

[337]  O. Rascol,et al.  Treatment of Parkinson's disease should begin with a dopamine agonist , 1999, Movement disorders : official journal of the Movement Disorder Society.

[338]  M. Millan,et al.  Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. , 1995, European journal of pharmacology.

[339]  B. Levant,et al.  Differential distribution of D3 dopamine receptors in the brains of several mammalian species , 1998, Brain Research.

[340]  M. E. Lajiness,et al.  Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. , 1995, European journal of pharmacology.

[341]  I. Gyertyán,et al.  Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference , 2003, Neuroreport.

[342]  F. Boeckler,et al.  Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. , 2005, Journal of medicinal chemistry.

[343]  J. Ballesteros,et al.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.

[344]  J. Waddington,et al.  Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach , 1998, Psychopharmacology.

[345]  E. Bézard,et al.  Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.

[346]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[347]  S. Fuchs,et al.  A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. , 1993, The Journal of biological chemistry.

[348]  Peter Gmeiner,et al.  Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. , 2005, Journal of medicinal chemistry.

[349]  M. Martres,et al.  Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[350]  R. Todd,et al.  Morphogenic potentials of D2, D3, and D4 dopamine receptors revealed in transfected neuronal cell lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[351]  P. Carvey,et al.  Mechanisms of action of pramipexole: Putative neuroprotective effects , 2001 .

[352]  F. Mcdowell,et al.  “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.

[353]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[354]  E. Lehr Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice , 2002, Psychopharmacology.

[355]  G. Hanson,et al.  Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. , 2003, European journal of pharmacology.

[356]  J. Brotchie,et al.  Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia , 2004, Experimental Neurology.

[357]  G. F. Lundell,et al.  Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists. , 1984, Journal of medicinal chemistry.

[358]  P. Sokoloff,et al.  Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. , 1995, The Journal of pharmacology and experimental therapeutics.

[359]  R. A. Fuchs,et al.  Increases in Dopamine D3 Receptor Binding in Rats Receiving a Cocaine Challenge at Various Time Points after Cocaine Self-Administration: Implications for Cocaine-Seeking Behavior , 2004, Neuropsychopharmacology.

[360]  J. Hagan,et al.  Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. , 2003, Journal of medicinal chemistry.

[361]  Erin E. Carlson,et al.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.

[362]  A. Fink-Jensen,et al.  Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. , 1998, European journal of pharmacology.

[363]  R. Pahwa,et al.  Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study , 2001 .

[364]  M. Martres,et al.  A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[365]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[366]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.

[367]  M. Piercey,et al.  Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease , 1999, Journal of the Neurological Sciences.

[368]  Harald Hübner,et al.  Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist. , 2005, Bioorganic & medicinal chemistry.

[369]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[370]  A. Schapira Dopamine agonists and neuroprotection in Parkinson's disease. , 2002, European journal of neurology.

[371]  J. Belluzzi,et al.  N‐0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[372]  N. Mohell,et al.  Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. , 1998, The Journal of pharmacology and experimental therapeutics.

[373]  J. Joyce,et al.  D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period , 2001, Synapse.

[374]  F. J. White,et al.  Dopamine D3 receptor mutant and wild‐type mice exhibit identical responses to putative D3 receptor‐selective agonists and antagonists , 1999, Synapse.

[375]  J. Meador-Woodruff Update on dopamine receptors. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[376]  H. Kung,et al.  Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand. , 1993, Journal of medicinal chemistry.

[377]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[378]  Glen L Alberts,et al.  Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents , 1998, British journal of pharmacology.

[379]  M. P. Turpin,et al.  Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.

[380]  M. Caron,et al.  Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. , 1997, Molecular pharmacology.

[381]  In Vivo Occupancy of D2Dopamine Receptors by Nafadotride , 1997, Neuropsychopharmacology.

[382]  H. Sahraei,et al.  Involvement of Dopamine Receptors of the Dorsal Hippocampus on the Acquisition and Expression of Morphine-Induced Place Preference in Rats , 2003, Journal of psychopharmacology.

[383]  P. Sokoloff,et al.  The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and d -amphetamine and is not self-administered , 2001, Behavioural pharmacology.

[384]  C. Reavill,et al.  Comparative Pharmacological Study of Ropinirole (SKF‐101468) and its Metabolites in Rats , 2000, The Journal of pharmacy and pharmacology.

[385]  Jonathan A Javitch,et al.  The Ants Go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors , 2004, Molecular Pharmacology.

[386]  S. Franklin,et al.  Discriminative stimulus properties of the dopamine D3 antagonist PNU-99194A , 1998, Psychopharmacology.

[387]  J. Cannon,et al.  Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline. , 1976, Journal of medicinal chemistry.

[388]  Christina Z Floresca,et al.  Dopamine Receptor Microdomains Involved in Molecular Recognition and the Regulation of Drug Affinity and Function , 2004, Journal of receptor and signal transduction research.